vimarsana.com
Home
Live Updates
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financia
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financia
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
/PRNewswire/ -- Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible...
Related Keywords
United States ,
American ,
Dana Cormack ,
Chris Brinzey ,
Ultragenyx Pharmaceutical Inc ,
Technology Platform ,
Technology Platform Licensees ,
Drug Administration ,
American Academy Of Ophthalmology ,
Rocket Pharmaceuticals Inc ,
Nasdaq ,
Novartis ,
Technology Licensee Program ,
Development Expenses ,
Exchange Commission ,
Corporate Communications ,
Securities Exchange ,
Orphan Drug Designation ,
Rare Pediatric Disease Designation ,
Chief Executive Officer ,
Investigational New Drug ,
Biologics Licensing Application ,
Duchenne Muscular Dystrophy ,
Hunter Syndrome ,
Good Manufacturing Practice ,
Manufacturing Facility ,
Licensee Program ,
Rocket Pharmaceuticals ,
Ultragenyx Pharmaceutical ,
Ornithine Transcarbamylase ,
Administrative Expenses ,
Platform Licensees ,
Securities Act ,
Securities Exchange Act ,
Financial Condition ,
Regenxbio Inc ,